ArticleAntibiotics (Basel, Switzerland)2023
Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06440304 (Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Therapeutic Strategies for Carbapenem-Resistant Acinetobacter Baumannii Infections: Study Protocol
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies.BMC infectious diseases · 2026Pooled it
- Pooled it
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement.Infectious diseases and therapy · 2026Article
- Innovative Antibiotics: The Experience of Cefiderocol in Carbapenem-Resistant Gram-Negative Infections.Infection and drug resistance · 2026Review
- Intravenous Fosfomycin for Gram-Negative and Gram-Positive Bacterial Infections: A Systematic Review of the Clinical Evidence.Antibiotics (Basel, Switzerland) · 2025Review
- Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): a narrative review.European journal of clinical pharmacology · 2025Review
- The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-ResistantMicroorganisms · 2025Review
- Eravacycline Treatment for Carbapenem-ResistantInfection and drug resistance · 2025Article
- Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Current issues in molecular biology · 2024Review
- The challenges of difficult-to-treatClinical microbiology reviews · 2024Review
- Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2024Review
- Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.Infectious diseases and therapy · 2024Article
- Challenges Facing Two Outbreaks of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Treatment of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2024Review
- Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study.Infection and drug resistance · 2024Article
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Editorial for the Special Issue: "The Issue of Multidrug-Resistant Pathogens in Nosocomial Infections".Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence-based, standard antibiotic therapy for ventilator-associated pneumonia (VAP) caused by carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.